M Ventures

We are excited to welcome Ally Bridge Group, EQT Life Sciences, M Ventures and Pfizer as official sponsors of the 25th Bio€quity Europe!   Ally Bridge Group is a global healthcare investment firm focused on private and public high-impact life science innovation. The firm has led or co-led over $6 billion in healthcare transactions. Their mission is to generate superior risk-adjusted returns for investors guided by the core principle of selective investment in healthcare innovation that addresses unmet medical needs.   EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported more than 150 companies over 30 years. With a dedicated team of experienced investment professionals from medicine, science, business, and finance, EQT Life Sciences backs inventors with ideas that could make a difference for patients.   M Ventures is the strategic, corporate venture capital fund of Merck KGaA. They invest in visionary companies that: treat challenging diseases, empower scientists with cutting-edge R&D tools, develop solutions for information access and processing, and address challenges in sustainability and technology convergence.   Pfizer applies science and their global resources to bring therapies to people that extend and significantly improve their lives. They strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Their global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.   On behalf of BioCentury Inc., EBD Group and Insights Partner McKinsey & Company, we are looking forward to having you at our CEO & investor Summit in Bruges, May 12-14, 2025.   Join biopharma leaders and VCs in Belgium as we dive into East-West dealmaking and debate what is next for the European biotech ecosystem. Register at www.bioequityeurope.com.   Download the conference brochure to review the agenda, presenting companies and who you will meet: https://lnkd.in/gFch8JnC View all sponsors: https://lnkd.in/gv9_vmFh

We’re excited to announce two key leadership appointments as Vizgen continues to expand its global impact in spatial multi-omics. Christian Uhrich, investment director at M Ventures has joined Vizgen’s Board of Directors, bringing extensive expertise in biopharma strategy, commercialization, and investment growth to support our long-term vision. Chad Brown has been appointed Chief Commercial Officer, leveraging his 30+ years of industry leadership experience at NanoString, QIAGEN, and Roche Diagnostics to drive commercial expansion and accelerate global access to Vizgen’s groundbreaking spatial biology technologies. “These additions to our board and leadership team underscore our strong commitment to advancing Vizgen and the field of spatial multi-omics toward their full potential, delivering value for our customers in foundational research and translational medicine. We are very pleased to have the support of M Ventures and, in particular, to benefit from Christian’s expertise in life sciences investments, strategy, and operations as he joins our board. Similarly, Chad brings exceptional commercial acumen and a proven track record of success, joining us at an exciting time as Vizgen enters a broad new product cycle,” said Rob Carson, CEO of Vizgen. Read more in today’s announcement: https://hubs.ly/Q03dk6bN0 #Vizgen #SpatialBiology #MultiOmics #Leadership #Biotech

Congrats to M Ventures portfolio company iOnctura for commencing the Phase II study in metastatic uveal melanoma!

M Ventures Hakan Goker sharing his dealmaker's perspective during the BIO-Europe panel "Day in the life of a experienced dealmaker". The panel also included Jenny Laird and Monika Vnuk, with moderation by Evonne Sepsis and Anton Gueth.

🚀 Celestial AI Secures $250 Million Funding to Revolutionize AI Infrastructure with Its #PhotonicFabric ⚡Series C1 funding round led by Fidelity Investments, bringing the total capital raised to date to more than $515 million. In addition to Fidelity Investments, new investors include funds and accounts managed by BlackRock, Maverick Silicon, Tiger Global Management and Lip-Bu Tan, as well as participation from existing investors including AMD Ventures, Koch Disruptive Technologies (KDT), Temasek, Xora Innovation, Porsche Automobil Holding SE and Engine Ventures. Find out more: www.celestial.ai Intelligence,Illuminated.

Does your startup have solutions which can help the #semiconductor industry become more #sustainable? Do you want to get input from the leading investors and industry experts? Do you need to help to figure out if the semiconductor market is right for your product and how to create maximum mutual value?   Then you need to take advantage of this opportunity to apply to Startups for Sustainable Semiconductors pitch event and mentorship program! Apply Here: 👉 https://lnkd.in/gHVgBubz The SEMI S3 Program is co-organized by leading semi CVCs including M Ventures and designed to help startups with sustainability solutions who may not be aware of the needs of the semiconductor sector or would benefit from introductions to the right teams for evaluation. The S3 program provides both mentoring and introductions. This year's categories include: 💡 Manufacturing: lower energy intensity, energy tracking and management, sustainable materials, emission control, water, PFAS destruction, and recycling 💡 Sustainable Data Centers: thermal and power management, new systems and components for efficiency gains 💡 Gen AI for Sustainable Design: energy efficient chip design, new materials discovery, simulation, end-to-end sustainable design #CVC #startups #startups4semiconductor #sustainable_semiconductors #EnergyCollaborative #startups4semi

Selective targeting and degradation of toxic protein aggregates remains highly challenging. Today we announce our investment in TRIMTECH Therapeutics Limited, which uses the novel TRIM21 degrader technology to tackle this challenge. Trimtech today announced a $31M Seed financing, in which we M Ventures co-invested with Cambridge Innovation Capital, SV Health Investors' Dementia Discovery Fund (DDF), Pfizer Ventures, MP Healthcare Venture Management (MPH), Eli Lilly and Company, Cambridge Enterprise Ventures, and Start Codon. Link to further information: https://lnkd.in/eMUNEaBa

Only one month to go till the 21st Anglonordic Life Science Conference, taking place April 3rd in London. M Ventures is the founding sponsor of this great networking opportunity for Life Science companies and European investors. Looking forward to seeing you in London.

We’re proud to share that M Ventures has been ranked as the #2 most active biotech investor in the UK by the BioIndustry Association (BIA) and as #67 most active globally by Endpoints News and DealForma, a reflection of our commitment to advancing breakthroughs in life sciences. Please find respective links in the comments. In 2024, we’ve: 🧬 Added 7 new companies to our biotech portfolio: ·      Abselion – lead investor in GBP6.6M Series A ·      Kivu Bioscience – USD92M Series A ·      Enara Bio – co-lead investor in GBP32.5M Series B ·      LabGenius Therapeutics – lead investor in GBP35M Series B ·      Outrun Therapeutics emerged from stealth mode – co-lead investor in GBP10M Seed ·      Nucleai – lead investor in USD14M financing ·      DISCO Pharmaceuticals GmbH emerged from stealth mode– EUR20M Seed 💊 Supported innovations across: ADCs, AI-driven histopathology, dark antigen discovery, protein stabilization, and many more 📈 Helped raise USD200M+ in follow-on funding for our portfolio ·      PictorLabs Inc – USD30M Series B ·      NanoSyrinx – GBP10M financing ·      Asceneuron SA – USD100M Series C ·      iOnctura – EUR80M Series B

M Ventures is joining the East-West Biopharma Summit next week in Singapore. Looking forward to connecting!